BioXcel Therapeutics, Inc. SEC filings BTAIQ
BioXcel Therapeutics, Inc. has 672 filings in SEC EDGAR's recent list, going back to Nov 13, 2017. Its latest annual report, Form 10-K, was filed on Mar 27, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 30, 2026 (acquisition or sale of assets, officer or director change, bylaw or fiscal year change). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Jan 17, 2025 | — |
| CORRESP | Letter to the SEC | Jan 15, 2025 | — |
| UPLOAD | Letter from the SEC | Jan 15, 2025 | — |
| EFFECT | Filing | Jan 22, 2024 | — |
| CORRESP | Letter to the SEC | Jan 19, 2024 | — |
| UPLOAD | Letter from the SEC | Jan 19, 2024 | — |
| EFFECT | Filing | Nov 13, 2023 | — |
| CORRESP | Letter to the SEC | Nov 13, 2023 | — |
| RW WD | Filing | Nov 13, 2023 | — |
| RW | Filing | Nov 13, 2023 | — |
| CORRESP | Letter to the SEC | Nov 9, 2023 | — |
| UPLOAD | Letter from the SEC | Nov 3, 2023 | — |
| EFFECT | Filing | Jun 16, 2022 | — |
| CORRESP | Letter to the SEC | Jun 14, 2022 | — |
| UPLOAD | Letter from the SEC | Jun 2, 2022 | — |
| DEL AM | Filing | May 31, 2022 | — |
| EFFECT | Filing | Apr 7, 2022 | — |
| POSASR | Filing | Mar 11, 2022 | — |
| EFFECT | Filing | Apr 4, 2019 | — |
| UPLOAD | Letter from the SEC | Apr 4, 2019 | — |
| CORRESP | Letter to the SEC | Apr 2, 2019 | — |
| RW | Filing | Apr 1, 2019 | — |
| CT ORDER | Filing | Dec 20, 2018 | — |
| CT ORDER | Filing | Mar 8, 2018 | — |
| EFFECT | Filing | Mar 7, 2018 | — |
| CORRESP | Letter to the SEC | Mar 5, 2018 | — |
| CORRESP | Letter to the SEC | Mar 5, 2018 | — |
| 8-A12B | Filing | Mar 5, 2018 | — |
| CORRESP | Letter to the SEC | Feb 23, 2018 | — |
| UPLOAD | Letter from the SEC | Feb 23, 2018 | — |
| CORRESP | Letter to the SEC | Feb 12, 2018 | — |
| CORRESP | Letter to the SEC | Feb 12, 2018 | — |
| UPLOAD | Letter from the SEC | Feb 5, 2018 | — |
| DRSLTR | Filing | Jan 26, 2018 | — |
| DRS/A | Filing | Jan 26, 2018 | — |
| UPLOAD | Letter from the SEC | Jan 16, 2018 | — |
| DRSLTR | Filing | Dec 27, 2017 | — |
| DRS/A | Filing | Dec 26, 2017 | — |
| DRSLTR | Filing | Dec 22, 2017 | — |
| UPLOAD | Letter from the SEC | Dec 12, 2017 | — |
| DRS | Filing | Nov 13, 2017 | — |
Showing 41 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BTAIQ (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New Haven, CT
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1720893
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.